F182112 single-agent

Phase 1

IInstitute of Hematology & Blood Diseases Hospital, China

F182112 single-agent is one of 2 therapeutic programs targeting Autoimmune Hemolytic Anemia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Autoimmune Hemolytic AnemiaNot yet recruiting

Autoimmune Hemolytic AnemiaPhase 1

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Autoimmune Hemolytic Anemia

#DrugCompanyPhaseTrials

YTS109 Cell

CChina Immunotech (Beijing) Biotechnology Co., Ltd.

Phase 1

1 2

F182112 single-agent

IInstitute of Hematology & Blood Diseases Hospital, China

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Autoimmune Hemolytic Anemia

NCT07816341

Clinical

Trials by Indication[1]

Autoimmune Hemolytic Anemia1 trial

A Phase 1 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of F182112 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07816341·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for F182112 single-agent. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for F182112 single-agent. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Institute of Hematology & Blood Diseases Hospital, China company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: IInstitute of Hematology & Blood Diseases Hospital, China

F182112 single-agent

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Autoimmune Hemolytic Anemia1 trial

References

Drug Info

Quick Facts

Related News